在有或没有使用激素治疗的绝经后妇女中,对塞马格卢提德的减肥反应
Maria D Hurtado, Elif Tama, Sima Fansa1
1Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Menopause (New York, N.Y.)
|March 6, 2024
概括
绝经后女性使用黄胺减肥的更年期激素治疗 (HT) 与显著更大的减肥有关. 这一发现表明HT可能会增强塞马格卢提德的作用.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 绝经后的女性经常出现超重或肥胖,增加心脏代谢风险.
- 塞马格卢提德是一种有效的减肥治疗方法,但在这种人群中,其与激素治疗 (HT) 结合的疗效不太清楚.
研究的目的:
- 为了比较体重减轻反应和心脏代谢风险标志物的变化,在经过更年期的女性使用西马格卢提德,并无同时进行更年期激素治疗 (HT).
主要方法:
- 一项回顾性队列研究分析了至少3个月用西马格卢提德治疗超重/肥胖症的绝经后妇女.
- 关键终点包括3,6,9和12个月的总体体重减轻百分比 (TBWL%),以及达到≥5%和≥10%的TBWL.
- 12个月后评估心脏代谢风险标志物 (葡萄糖,血压,脂质) 的变化.
主要成果:
- 使用HT的女性 (n=16) 与不使用HT的女性 (n=90) 相比,在所有时间点都显示出明显更高的TBWL%.
- 在12个月后,HT使用者实现了更高的TBWL% (16% vs 12%) 和更高的≥5%和≥10%的体重减轻率.
- 两组都在心脏代谢风险标志物上表现出改善,HT使用者表现出更大益处的趋势.
结论:
- 在患有超重或肥胖的绝经后妇女中,同时使用HT与塞马格卢提德与改善的减肥反应有关.
- 在对潜在混因素进行调整后,这种关联仍然存在,这表明有协同效应.
- 需要进行更大规模的前性研究来证实这些发现并阐明潜在的机制.
相关概念视频
01:16Insulin: Dosing Regimen and Adverse Effects
170
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
170
01:15Hypoglycemia and Glucagon
260
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
260
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
01:24Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:22Target Cell Response to Hormones
3.0K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
3.0K